Abstract:Central nervous system (CNS) drugs have had a significant impact on human health, e.g., treating a wide range of neurodegenerative and psychiatric disorders. In recent years, deep learning-based generative models, particularly those for designing drugs from scratch, have shown great potential for accelerating drug discovery, reducing costs and improving efficacy. However, specific applications of these techniques in CNS drug discovery have not been widely reported. In this study, we developed the CNSMolGen model, which uses a bidirectional recurrent neural networks (Bi-RNNs) system for de novo molecular design of CNS drugs by learning from compounds with CNS drug properties. Result shown that the pre-trained model was able to generate more than 90% of completely new molecular structures, and these new molecules possessed the properties of CNS drug molecules and synthesizable. In addition, transfer learning was performed on small datasets with specific biological activities to evaluate the potential application of the model for CNS drug optimization. Here, we used drugs against the classical CNS disease target serotonin transporter (SERT) as a fine-tuned dataset and generated a Focused database against the target protein. The potential biological activities of the generated molecules were verified using the physics-based induced fit docking study. The success of this model demonstrates its potential in CNS drug design and optimization, which provides a new impetus for future CNS drug development.

Universal Approach to De Novo Drug Design for Target Proteins Using Deep Reinforcement Learning

Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

De Novo Structure-Based Drug Design Using Deep Learning

Deep Learning Approaches for &lt;italic&gt;de Novo&lt;/italic&gt; Drug Design: an Overview

Deep learning approaches for <i>de novo</i> drug design: An overview

De Novo Drug Design Against SARS-CoV-2 Protein Targets Using SMILES-based Deep Reinforcement Learning.

Deep learning approaches for de novo drug design: An overview

Prospective de novo drug design with deep interactome learning

De novo drug design based on Stack-RNN with multi-objective reward-weighted sum and reinforcement learning

De novo design of protein target specific scaffold-based Inhibitors via Reinforcement Learning

De novo drug design using reinforcement learning with graph-based deep generative models

De novo drug design framework based on mathematical programming method and deep learning model

Status and Prospects of Research on Deep Learning-based De Novo Generation of Drug Molecules

Utilizing reinforcement learning for de novo drug design

De novo Drug Design using Reinforcement Learning with Multiple GPT Agents

Advancing Drug Discovery with Deep Learning: Harnessing Reinforcement Learning and One-Shot Learning for Molecular Design in Low-Data Situations

Advances in De Novo Drug Design: From Conventional to Machine Learning Methods

CNSMolGen: a bidirectional recurrent neural networks based generative model for de novo central nervous system drug design

De novo drug design by iterative multiobjective deep reinforcement learning with graph-based molecular quality assessment

Designed with interactome-based deep learning